AR055420A1 - SUBSTITUTED PIRIMIDINE DERIVATIVES - Google Patents

SUBSTITUTED PIRIMIDINE DERIVATIVES

Info

Publication number
AR055420A1
AR055420A1 ARP060103924A ARP060103924A AR055420A1 AR 055420 A1 AR055420 A1 AR 055420A1 AR P060103924 A ARP060103924 A AR P060103924A AR P060103924 A ARP060103924 A AR P060103924A AR 055420 A1 AR055420 A1 AR 055420A1
Authority
AR
Argentina
Prior art keywords
alq
ilo
cycloalq
yloxy
halo
Prior art date
Application number
ARP060103924A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR055420A1 publication Critical patent/AR055420A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula general (1) donde: q es 0 o 1; R1 y R2 se seleccionan independientemente del grupo integrado por H y opcionalmente sustituido aril-alq(en/in)ilo C1-6, siempre que R1 y R2 no sean ambos H, o R1 y R2 junto con el N al cual ellos están unidos forman un anillo de 5 a 7 miembros que contiene opcionalmente otro heteroátomo; R3 y R4 se seleccionan independientemente de H, halogeno, ciano, amino, alq(en/in)ilo C1-6, cicloalq(en)ilo C3-8, halo- alq(en/in)ilo C1-6, halo-cicloalq(en)ilo C3-8 alq(en/in)iloxi C1-6, cicloalq(en)iloxi C3-8, cicloalq(en)il C3-8-alq(en/in)iloxi C1-6, halo-alq(en/in)iloxi C1-6, halo-cicloalq(en)iloxi C3-8 y halo-cicloalq(en)il C3-8-alq(en/in)iloxi C1-6, siempre que R3 y R4 no sean ambos H; R5 se selecciona del grupo integrado por alq(en/in)ilo C1-10, cicloalq(en)il C3-8-alq(en/in)ilo C1-6, opcionalmente sustituido aril-alq(en/in)ilo C1-6- y arilo opcionalmente sustituido; como base libre a sus sales.Claim 1: A compound having the general formula (1) wherein: q is 0 or 1; R1 and R2 are independently selected from the group consisting of H and optionally substituted aryl-alq (en / in) ilo C1-6, provided that R1 and R2 are not both H, or R1 and R2 together with the N to which they are attached they form a 5 to 7 member ring that optionally contains another heteroatom; R3 and R4 are independently selected from H, halogen, cyano, amino, alq (en / in) C1-6 yl, cycloalk (en) C3-8 yl, haloalq (en / in) C1-6 ilo, halo- cycloalq (en) C3-8 yl alq (en / in) C1-6 yloxy, cycloalq (en) C3-8 yloxy, C3-8-cycloalk (en) and C1-6 yloxy, halo- alq (en / in) C1-6 iloxy, halo-cycloalq (en) C3-8 yloxy and halo-C3-8-alq (en / in) C1-6 iloxy, provided that R3 and R4 do not be both H; R5 is selected from the group consisting of alq (en / in) ilo C1-10, cycloalq (en) and C3-8-alq (en / in) ilo C1-6, optionally substituted aryl-alq (en / in) ilo C1 -6- and optionally substituted aryl; as a free base for its salts.

ARP060103924A 2005-09-09 2006-09-08 SUBSTITUTED PIRIMIDINE DERIVATIVES AR055420A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09

Publications (1)

Publication Number Publication Date
AR055420A1 true AR055420A1 (en) 2007-08-22

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103924A AR055420A1 (en) 2005-09-09 2006-09-08 SUBSTITUTED PIRIMIDINE DERIVATIVES

Country Status (15)

Country Link
EP (1) EP1937653A1 (en)
JP (1) JP2009507052A (en)
KR (1) KR20080043314A (en)
CN (1) CN101258133A (en)
AR (1) AR055420A1 (en)
AU (1) AU2006322461A1 (en)
BR (1) BRPI0615631A2 (en)
CA (1) CA2621854A1 (en)
EA (1) EA200800780A1 (en)
IL (1) IL189545A0 (en)
MX (1) MX2008002294A (en)
NO (1) NO20081713L (en)
UA (1) UA93387C2 (en)
WO (1) WO2007065449A1 (en)
ZA (1) ZA200802174B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (en) * 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
AU2011275393B2 (en) * 2010-07-08 2014-04-10 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CA2815131C (en) * 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
CN103508960B (en) * 2012-06-29 2017-12-12 江苏先声药业有限公司 Benzheterocyclic derivatives
CN103508943B (en) * 2012-06-29 2017-06-09 江苏先声药业有限公司 As the compound of potassium channel modulating agents
MX2017005044A (en) 2014-10-24 2017-07-04 Ono Pharmaceutical Co Kcnq2-5 channel activator.
JP2022543230A (en) * 2019-08-02 2022-10-11 ハー・ルンドベック・アクチエゼルスカベット Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or epileptic seizures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508833A (en) * 2001-02-20 2005-04-07 ブリストル−マイヤーズ　スクイブ　カンパニー 2,4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
AU2003202115A1 (en) * 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
WO2007065449A1 (en) 2007-06-14
KR20080043314A (en) 2008-05-16
AU2006322461A1 (en) 2007-06-14
NO20081713L (en) 2008-06-04
CN101258133A (en) 2008-09-03
UA93387C2 (en) 2011-02-10
ZA200802174B (en) 2009-10-28
IL189545A0 (en) 2008-06-05
EP1937653A1 (en) 2008-07-02
MX2008002294A (en) 2008-03-14
EA200800780A1 (en) 2008-06-30
BRPI0615631A2 (en) 2011-05-24
JP2009507052A (en) 2009-02-19
CA2621854A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
AR055420A1 (en) SUBSTITUTED PIRIMIDINE DERIVATIVES
AR055144A1 (en) ACID SECRETION INHIBITOR
PE20061297A1 (en) CHROME AND CHROME DERIVED COMPOUNDS MODULATING THE SEROTONIN 5-HT2C RECEPTOR
AR058776A1 (en) CONDENSED PYRIDINE COMPOUND
AR049784A1 (en) SUBSTITUTED DERIVATIVES OF MORFOLINA AND TIOMORFOLINA
ECSP11010912A (en) PIRROL COMPOUNDS
ECSP055974A (en) SYNTHESIS OF CHLORIDES OF 4 AMINO-2-BUTENOIL AND ITS USE IN THE PREPARATION OF 3-CYANO QUINOLINAS
AR077695A1 (en) PIRIMIDINE DERIVATIVES AS INHIBITORS OF FACTOR IXA
AR062677A1 (en) DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR048778A1 (en) PIRROLIDINYL DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXIESTEROID DEHYDROGENASE
AR052568A1 (en) DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2
CR10784A (en) NEW DERIVATIVES OF AMINOPIRIMIDINE AS PLKI INHIBITORS
AR053739A1 (en) ESPIRO COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONA SINTASA
ECSP055987A (en) HETEROARILCARBAMOILBENCENO DERIVATIVES
PE20071322A1 (en) DERIVATIVES OF 2-MORPHOLINOPYRIMIDINE AS INHIBITORS OF PHOSPHATIDINOINOSITOL (PI) 3-KINASE
AR054369A1 (en) CONDENSED IMIDAZOL COMPOUNDS AND ITS USE AS ALDOSTERONE SINTASA INHIBITORS
AR048055A1 (en) PIRIMIDINE DERIVATIVES AS INHIBITORS OF DIPEPTIDIL PEPTIDASA
CR9459A (en) BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME
ES2422204T3 (en) Novel derivatives of imidazolidin-2-one as selective androgen receptor modulators (SARMS)
CO6270314A2 (en) A Y-DERIVATIVE - AMINO BICYCLE ACID THAT HAS AN ACTIVITY AS A BINDING (ALPHA) 2 (OMEGA)
UY30897A1 (en) PENTAFLUOROTIOBENZAMIDOACETONITRILE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND APPLICATIONS
PE20080068A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINE AS INHIBITORS OF KINASE AURORA
AR069480A1 (en) DERIVATIVES OF 2-AMINO-PYRIMIDINE
AR051392A1 (en) NON-PEPTIDIC ANTAGONISTS OF BRADIQUININE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
AR078606A1 (en) PIPERIDINE DERIVATIVES TO PREVENT AND / OR TREAT DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Legal Events

Date Code Title Description
FA Abandonment or withdrawal